Sunday, January 29, 2023
  • Home
  • Markets & Companies
  • Business & Economy
  • INNOVATION
  • EMPIRE
  • OPINION
  • CULTURAL CURRENTS
  • Features
  • AE Magazine
  • CORPORATE RENDEZVOUS
Financial Street
No Result
View All Result
  • Home
  • Markets & Companies
  • Business & Economy
  • INNOVATION
  • EMPIRE
  • OPINION
  • CULTURAL CURRENTS
  • Features
  • AE Magazine
  • CORPORATE RENDEZVOUS
Financial Street
No Result
View All Result

GSK, Novartis support Africa’s scientific research with $3.6m grant

Ehime Alex by Ehime Alex
January 20, 2021
in Markets & Companies
0
GSK, Novartis support Africa's scientific research with $3.6m grant
0
SHARES
36
VIEWS
Share on FacebookShare on TwitterShare on LinkedInShare on WhatsApp

READ ALSO

Afrinvest, Interswitch, Obiano, UBA lead top 10 performing brands

Afrinvest Asset gets A3 Rating, Agusto assigns A

GSK and Novartis have called on African researchers to submit research proposals on the relevance of African genetic diversity to the treatment of malaria and tuberculosis.

The ‘Project Africa Genomic Research Approach for Diversity and Optimising Therapeutics’ comes with a combined funding commitment of $3.6 million over five years, Novartis said in a statement on Tuesday.

The combined effort will support high-quality scientific research investigating the link between genetic diversity across different regions in Africa and its potential impact on response to drug therapeutics.

Read Also:

  • Afrinvest, Interswitch, Obiano, UBA lead top 10 performing brands
    Afrinvest, Interswitch, Obiano, UBA lead top 10 performing…
  • Absence of sacrifice hurting our polity, elections – Enechionyia
    Absence of sacrifice hurting our polity, elections –…
  • Scholarly opportunities in W’Africa and youth development
    Scholarly opportunities in W’Africa and youth development

“Novartis has a long-standing commitment to improving and extending the lives of patients around the world.  Our efforts include seeking innovative ways to improve the standard of care where possible. This is why we are excited by this important collaboration on scientific research on genetic diversity in Africa.

“It has the potential to improve the efficacy and tolerability of current and future medicines, starting with two of the most deadly diseases, malaria and tuberculosis,” Chief Operating Officer for Global Health at Novartis, Lutz Hegemann, said.

Also commenting on the project, Senior Vice President Global Health Pharma at GSK, Pauline Williams, explained, “At GSK, human genetics is a core pillar of our research and development strategy. Genetic diversity is greater in Africa than in any other continental population resulting in some African patients having varying responses to treatments.

“We are excited to launch Project Africa GRADIENT which aims to catalyse the best science in the continent to optimise treatment responses for malaria and tuberculosis, two infectious diseases that disproportionately affect African populations.”

The project’s funding mechanisms include fellowships, investigator-sponsored research, and seed-fund and will give priority to research aimed at collecting data from currently under-represented regions.

Tags: AfricaGSKNovartScientific research

Get real time update about this post categories directly on your device, subscribe now.

Unsubscribe
Ehime Alex

Ehime Alex

Ehime Alex reports the Capital Market, Energy, and ICT. He is a skilled webmaster and digital media enthusiast.

Related Posts

Brands in Nigeria
Front Page

Afrinvest, Interswitch, Obiano, UBA lead top 10 performing brands

January 25, 2023
Afrinvest Asset
Front Page

Afrinvest Asset gets A3 Rating, Agusto assigns A

December 5, 2022
NGX ASI closes in green
Front Page

NGX ASI closes in green with 1.22% increase

November 21, 2022
NGX ASI closes in green
Front Page

NGX ASI dips by 0.68%, closes at N23.949tn

November 14, 2022
NGX ASI closes in green
Front Page

Bullish move heralds NGX Nov trade

November 7, 2022
NGX ASI closes in green
Front Page

NGX ASI closes in red

October 31, 2022
Next Post
Remarks of AfDB president, Adesina, at CIBN fellowship investiture

AfCFTA: Adesina honoured for leadership role


Naira4Dollar Rates
ADVERTISEMENT

RECENT STORIES

Zelenskyy

Zelenskyy names Ezekwesili, others ‘Grain from Ukraine’ envoys

January 27, 2023
Absence of sacrifice hurting our polity, elections – Enechionyia

Absence of sacrifice hurting our polity, elections – Enechionyia

January 26, 2023
Brands in Nigeria

Afrinvest, Interswitch, Obiano, UBA lead top 10 performing brands

January 25, 2023
Rhodes Scholarships

Scholarly opportunities in W’Africa and youth development

January 24, 2023
Christmas and New Year holidays

Frustration of bank customers during public holidays

January 17, 2023

OAA agency celebrates as founder joins tourism experts

January 14, 2023
Ehizua Hub

Ehizua Hub, Igbinedion launch IUO Okada Hub

January 14, 2023

TRENDING

  • Brands in Nigeria

    Afrinvest, Interswitch, Obiano, UBA lead top 10 performing brands

    0 shares
    Share 0 Tweet 0
  • Scholarly opportunities in W’Africa and youth development

    0 shares
    Share 0 Tweet 0
  • Oke Layipo: A wasting goldmine

    2 shares
    Share 0 Tweet 0
  • Case for petty trading and investment in Nigeria

    0 shares
    Share 0 Tweet 0
  • Absence of sacrifice hurting our polity, elections – Enechionyia

    0 shares
    Share 0 Tweet 0
Financial Street

© Financial Street 2021. All Rights Reserved.

More Links

  • Privacy Policy
  • Terms of Use
  • Contact Us

Follow Us

No Result
View All Result
  • HOME
  • CONSUMER PERSPECTIVE
  • PERSONAL FINANCE
  • MARKETS & COMPANIES
    • APPOINTMENTS
    • COMMODITIES
    • COMPANIES
  • BUSINESS & ECONOMY
    • AGRICULTURAL ECONOMY
    • AGRO-ECONOMY
    • AVIATION
    • BRANDS
    • CONSUMER GOODS
    • ECONOMY
    • ENERGY
    • ENVIRONMENT
    • FINANCIAL INCLUSION
    • INSURANCE & PENSIONS
    • INVESTMENT
    • MANUFACTURING
    • MARITIME
    • MONEY
    • MSMEs
    • PRODUCT REVIEW
    • STARTUPS
  • CULTURAL CURRENTS
  • EMPIRE
  • CORPORATE RENDEZVOUS